Obesity Interventions | Market Insights | US | 2024
The US obesity intervention device market will show modest growth over the forecast period. Rising use of GLP-1 receptor agonists for obesity treatment will temporarily slow the growth of bariatric procedures, affecting device sales. The internal closure device market will continue to generate the highest proportion of obesity intervention device revenues over the forecast period due to their applicability in the majority of surgical procedures. However, continued innovation and product launches in the surgical stapler space will also support the penetration of these devices into bariatric surgeries. Moving forward, market growth will be driven by the introduction of innovative technologies and the FDA approval of these products. These advanced products are anticipated to command higher prices and contribute to strong market growth over the forecast period.
This Medtech 360 report provides comprehensive data and analysis on the state of the obesity intervention market in the US from 2019 through 2032.
